Surrozen (SRZN) Payables (2020 - 2026)

Surrozen (SRZN) recorded quarterly Payables of $889000.0 in Q1 2026, up 22.12% quarter-over-quarter from $728000.0 in Q4 2025, and up 194.37% on a YoY basis from $302000.0 in Q1 2025.

Surrozen (SRZN) Payables (2020 - 2026) Analysis & Trends

Surrozen's Payables history runs 7 years deep, the most recent figure standing at $889000.0 for Q1 2026.

  • In Q1 2026, Payables rose 194.37% year-over-year to $889000.0; the TTM figure through Mar 2026 stood at $889000.0 (up 194.37% YoY), while the FY2025 annual figure was $728000.0, up 137.91% from the prior year.
  • Payables was $889000.0 for Q1 2026 at Surrozen, up from $728000.0 in the prior quarter.
  • In the past five years, Payables ranged from a high of $1.0 million in Q1 2022 to a low of $131000.0 in Q1 2024.
  • Historically, Payables has averaged $432294.1 across 5 years, with a median of $354000.0 in 2025.
  • The sharpest annual moves came in 2023 and 2026: Payables tumbled 83.64% in 2023, then jumped 194.37% in 2026.
  • A 5-year view of Payables shows it stood at $658000.0 in 2022, then decreased by 20.21% to $525000.0 in 2023, then plunged by 41.71% to $306000.0 in 2024, then soared by 137.91% to $728000.0 in 2025, then climbed by 22.12% to $889000.0 in 2026.
  • The last three Payables figures came in at $889000.0 (Q1 2026), $728000.0 (Q4 2025), and $538000.0 (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Payables (Qtr)
1 Alterity Therapeutics 719,706.53 Bn 719,706.50 Bn - 1.05 Mn
2 Belite Bio 55,800.00 Bn 55,800.00 Bn - -
3 Quantum Biopharma 18,182.30 Bn 18,182.29 Bn - 300,549.00
4 Legend Biotech 3,154.00 Bn 3,153.71 Bn 242.10 Mn 83.00 Mn
5 Akari Therapeutics 1,844.30 Bn 1,844.29 Bn - 8.69 Mn
6 Evaxion A 1,567.96 Bn 1,567.94 Bn - -
7 Psyence Biomedical 251.43 Bn 251.42 Bn - -
8 Vertex Pharmaceuticals 112.56 Bn 105.31 Bn 2.59 Bn 489.30 Mn
9 Abivax 94.37 Bn 94.37 Bn - 34.55 Mn
10 Surrozen 225,877.86 -106.68 Mn - 889,000.00

Historic Data

Download Data
DateValue
Mar 31, 2026 889,000.00
Dec 31, 2025 728,000.00
Sep 30, 2025 538,000.00
Jun 30, 2025 354,000.00
Mar 31, 2025 302,000.00
Dec 31, 2024 306,000.00
Sep 30, 2024 276,000.00
Jun 30, 2024 173,000.00
Mar 31, 2024 131,000.00
Dec 31, 2023 525,000.00
Sep 30, 2023 287,000.00
Jun 30, 2023 186,000.00
Mar 31, 2023 171,000.00
Dec 31, 2022 658,000.00
Sep 30, 2022 362,000.00
Jun 30, 2022 418,000.00
Mar 31, 2022 1.05 Mn
Dec 31, 2021 2.72 Mn
Sep 30, 2021 1.83 Mn
Dec 31, 2020 1.78 Mn